A Phase 1 Open-label Study of Safety and Tolerability of MEDI4736 in Subjects With Metastatic or Unresectable Melanoma in Combination With Dabrafenib and Trametinib or With Trametinib Alone
Phase of Trial: Phase I
Latest Information Update: 20 May 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Dabrafenib; Trametinib
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors MedImmune
- 09 May 2018 Status changed from active, no longer recruiting to completed.
- 14 Nov 2016 Planned End Date changed from 1 Oct 2017 to 1 Apr 2017.
- 14 Nov 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Apr 2017.